LORAZEPAM 0.5mg Tablets

Product strength addressing a therapy gap

Available dossier from Q4/2022

- **Indicated for** short term (2-4 weeks only) use (adults only)
  - Symptomatic relief of anxiety that is severe, disabling or subjecting the individual to unacceptable distress occurring alone or in association with insomnia or short-term psychosomatic, organic or psychotic illness
  - As premedication (adults and children 5 years and above)
  - Before operative dentistry and general surgery

Available strength: 0.5mg

0.5mg is specially used in patients with renal or hepatic impairment

- Patients with impaired renal or hepatic function have recommendation of lower doses as per SmPC of Lorazepam

Reference markets

- Lorazepam continues to be one of the main therapies, with sales of 2.1b tablets (MAT Q2 2022) and growing, as per IQVIA (EU27+UK)

Regulatory pathway

- Legal basis: Article 10(3) hybrid application

Development status

- EU dossier available from Q4/2022

Partnership options

- Dossier for selected markets on exclusive or semi-exclusive base or license
- Dossier can be adjusted to markets outside Europe based on request

Zentiva Group a.s.
U Kabelovny529/16, 102 00 Prague 10, Czech Republic

Zent2U@zentiva.com
+420 267243231

www.Zent2U.com